Inventiva S.A.
Close on Oct 19, 2026
About Inventiva
Pharmaceutical Preparations, SIC 2834
Inventiva S.A. is a clinical-stage biopharmaceutical company that develops oral small molecule therapies targeting metabolic dysfunction-associated steatohepatitis (MASH). Its sole drug candidate in active development is lanifibranor, a pan-PPAR activator designed to induce anti-fibrotic, anti-inflammatory, and metabolic improvements in patients suffering from progressive liver diseases. The company previously pursued earlier-stage oncology and genetic disorder programs, but it has discontinued non-lanifibranor research to dedicate all resources to its lead compound. Its prospective end users are adult patients diagnosed with MASH, non-alcoholic fatty liver disease, and related liver conditions such as compensated cirrhosis.
The company is headquartered in Daix, France, where it maintains executive offices and research facilities. Its workforce includes a development team of 47 individuals alongside one dedicated research specialist. Inventiva operates internationally through clinical trials and regional collaboration agreements covering territories such as the United States, China, and Japan. In addition, the organization holds patent protections spanning several dozen jurisdictions worldwide, including approximately 241 issued patents across roughly 55 countries outside the United States.
Summary of the business section of Inventiva's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Inventiva S.A.
- Founded
- 2011
- Headquarters
- Daix, I0
- Address
- 50 Rue De Dijon 21121
- Phone
- 33380447500
- Website
- inventivapharma.com
- Employees
- 77, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- I0
- Fiscal year ends
- December 31
- Auditor
- KPMG SA, Paris La Defense, France
Stock & identifiers
- Ticker
- IVA
- Other tickers
- IVEVF
- Exchange
- Nasdaq
- IPO date
- Jul 13, 2020
- Shares outstanding
- 193M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1756594
- CUSIP
- 46124U107
- ISIN
- US46124U1079
- LEI
- 969500I9Y690B3FZW590
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Inventiva's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 77 employees, 69 of whom were full-time employees and 8 of whom were part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 13, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 7, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |